BMY
Bristol-Myers SquibbCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Successful late-stage readouts or favorable regulatory outcomes plus stable core product sales drive multiple expansion toward the analyst high; acquisition or clearer long-term guidance could lift the stock to the bull target.
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.6.
What can break
Clinical trial failure or delay
Momentum
43
Value
70
Sentiment
51
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $57.68 · Bull $68.00 · Bear $37.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-02-06 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $61.83
Why
Momentum43 · Δ7d -10.4
Value70 · Δ7d +0.6
Sentiment51 · Δ7d +11.2
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
43
34% active weight
Current posture
7d trendSoftening
Δ7d
-10.4
Δ21d
+7.7
Value
70
32% active weight
Current posture
7d trendFlat
Δ7d
+0.6
Δ21d
+0.6
Sentiment
51
33% active weight
Current posture
7d trendImproving
Δ7d
+11.2
Δ21d
+9.1
Why this grade
Composite grade C. Momentum 43.0 / Value 69.7 / Sentiment 50.9
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$112.21B
Beta
0.29
Shares Out
2.04B
P/E (TTM)
17.9
P/S (TTM)
2.25
P/FCF (TTM)
10.49
Rev YoY
+2.8%
EPS YoY
+81.0%
Gross Margin
+73.1%
Op Margin
+20.0%
Net Debt
$38.79B
Current Ratio
1.27
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology